Inovelon contains rufinamide, which is an antiepileptic medicine. It is used to treat seizures associated with Lennox-Gastaut syndrome.
Active substance(s) | Rufinamide |
Country of admission | gb |
Marketing authorisation holder | Eisai Ltd. |
ATC Code | N03AF03 |
Pharmacological groups | Antiepileptics |
Inovelon contains rufinamide, which is an antiepileptic medicine. It is used to treat seizures associated with Lennox-Gastaut syndrome.
Please consult your doctor, even if these statements were applicable to you at any time in the past.
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
If your doctor prescribes or recommends an additional treatment for epilepsy (e.g. valproate) you must tell him you are taking Inovelon as your dose may need adjusting.
Inovelon should preferably be taken with food. As a precaution, do not take Inovelon with alcohol.
If you are a woman of childbearing age, you must use contraceptive measures while taking Inovelon.
If you are pregnant, or think you might be pregnant, or are planning to get pregnant, tell your doctor. You must only take Inovelon during your pregnancy if your doctor tells you to.
You must not breast-feed while taking Inovelon.
Ask your doctor or pharmacist for advice before taking any medicine.
Do not drive or operate machinery if you feel drowsy, dizzy or experience blurred vision whilst taking this medicine. Be particularly careful at the start of treatment or after your dose is increased.
Inovelon contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
Always take Inovelon exactly as your doctor has told you. You must check with your doctor or pharmacist if you are not sure.
Inovelon tablets must be taken twice daily with water, in the morning and in the evening. Inovelon can be taken with food. If you have difficulty swallowing, you can crush the tablet. Then mix the powder in about half a glass (100 ml) of water and drink immediately.
The usual starting dose in children weighing less than 30 kg is 200 mg a day taken in two doses. The dose will be adjusted for you by your doctor and may be increased by 200 mg at intervals of two days, to a daily dose of no more than 1000 mg.
The usual starting dose in adults and children weighing 30 kg or over is 400 mg a day taken in two doses. The dose will be adjusted for you by your doctor and may be increased by 400 mg at intervals of two days, to a daily dose of no more than 3200 mg, depending upon your weight.
Some patients may respond to lower doses. The dose may be increased more slowly if you experience side effects.
Inovelon is meant to be taken as a long-term medicine. Do not reduce your dose or stop your medicine unless your doctor tells you to.
If you may have taken more Inovelon than you should, tell a carer (relative or friend), your doctor or pharmacist immediately, or contact your nearest hospital casualty department, taking your medicine with you. You may become sleepy and could lose consciousness. Do not drive at this time.
If you forget to take a dose, continue taking your medicine as normal. Do not take a double dose to make up for forgotten dose. If you miss more than one dose, seek advice from your doctor.
If your doctor advises you to stop treatment, follow your doctor?s instructions concerning the gradual reduction of Inovelon in order to lower the risk of an increase in seizures.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, Inovelon can cause side effects, although not everybody gets them.
Tell your doctor if you have any of the following and if they are too uncomfortable for you:
Very common (more than 1 in 10 patients) side effects of Inovelon are:
Dizziness, headache, nausea, vomiting, sleepiness, fatigue.
Less commonly reported (more than 1 in a 100 patients) side effects of Inovelon are:
Problems associated with nerves including: difficulty walking, abnormal movement, convulsions/seizures, unusual eye movements, blurred vision, trembling.
Problems associated with the stomach including: stomach pain, constipation, indigestion, loose stools (diarrhoea), loss or change in appetite, weight loss.
Infections: Ear infection, flu, nasal congestion, chest infection.
In addition patients have experienced: anxiety, insomnia, nose bleeds, acne, rash, back pain, infrequent periods, bruising, head injury.
Uncommon (between 1 in a 100 and 1 in a 1000 patients) side effects of Inovelon are:
Allergic reactions and an increase in markers of liver function (hepatic enzyme increase).
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Keep Inovelon out of the reach and sight of children.
Do not use Inovelon after the expiry date which is stated on the blister and carton.
Do not store above 30°C.
Do not use Inovelon if you notice a change in colour of the tablets.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.
They are available as packs of 10, 30, 50, 60,100 and 200 film-coated tablets.
Marketing Authorisation Holder:
Eisai Ltd, Mosquito Way, Hatfield, Herts, AL10 9SN, UK.
Manufacturer:
Eisai Manufacturing Ltd, Mosquito Way, Hatfield, Herts, AL10 9SN, United Kingdom
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder:
BelgiëBelgiqueBelgien Eisai Europe Ltd. TélTel 32 0 2 735 45 34 LuxembourgLuxemburg Eisai Europe Ltd. TélTel 32 0 2 735 45 34 BelgiqueBelgien
Magyarország Eisai GesmbH Tel. 36 1 230 43 20 Eisai Ltd. Tel 44 0208 600 1400
eská republika Eisai GesmbH organizaní sloka Tel 420 242 485 839 Malta Associated Drug Company Ltd Tel 356 02277 8000
Nederland Eisai BV. Tel 31 0900 575 3340 Danmark Eisai AB Tlf 46 08 501 01 600 Sverige
Deutschland Eisai GesmbH Tel 49 0 696 65 85-0 Norge Eisai AB Tlf 46 08 501 01 600 Sverige
Österreich Eisai GesmbH Tel 43 0 1 535 1980-0 Eesti Eisai Ltd. Tel 44 020 8600 1400 Ühendkuningriik
Arriani Pharmaceuticals S.A. 30 210 668 3000 Polska Eisai Ltd. Tel. 44 0208 600 1400 Wielka Brytania
España Eisai Farmacéutica, S.A. Tel 34 91 455 94 55 Portugal Eisai Farmacêutica, Unipessoal Lda Tel 351 21 487 55 40
France Eisai SAS Tél 33 1 47 67 00 05 Romania Eisai Ltd. Tel 44 0208 600 1400 Marea Britanie
Ireland Eisai Ltd. Tel 44 0208 600 1400 United Kingdom Slovenija Eisai Ltd Tel 44 0208 600 1400 Velika Britanija
Ísland Eisai AB Sími 46 08 501 01 600 Svíjóð Slovenská republika Eisai GesmbH organizaní sloka Tel 420 242 485 839 eská republika
Italia Eisai S.r.l. Tel 39 02 5181401 SuomiFinland Eisai AB PuhTel 46 08 501 01 600 RuotsiSverige
Arriani Pharmaceuticals S.A. 30 210 668 3000 Sverige Eisai AB Tel 46 08 501 01 600
United Kingdom Eisai Ltd. Tel 44 0208 600 1400 Latvija Eisai Ltd. Tel 44 0208 600 1400 Liebritnija
Lietuva
Eisai Ltd.
Tel: + 44 (0)208 600 1400
(Jungtin- Karalyst-)
This leaflet was last approved in {MM/YYYY}.
Last updated on 22.08.2022
The following drugs also contain the active ingredient Rufinamide. Consult your doctor about a possible substitute for Inovelon 200 mg film-coated tablets
Browse our extensive database of medications from A-Z, including effects, side effects, and dosage.
All active ingredients with their effects, applications, and side effects, as well as the medications they are contained in.
Symptoms, causes, and treatments for common diseases and injuries.
The presented content does not replace the original package insert of the medication, especially regarding the dosage and effects of individual products. We cannot assume liability for the accuracy of the data, as the data has been partially converted automatically. Always consult a doctor for diagnoses and other health-related questions.
© medikamio